Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT00818662
Previous Study | Return to List | Next Study

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

This study has been completed.
Sponsor:
Collaborator:
Alzheimer's Disease Cooperative Study (ADCS)
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00818662
First received: January 7, 2009
Last updated: October 23, 2014
Last verified: October 2014

January 7, 2009
October 23, 2014
December 2008
December 2012   (final data collection date for primary outcome measure)
  • Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.

    Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

  • Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) [ Time Frame: Baseline & 18 Months ] [ Designated as safety issue: No ]

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.

    Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

Cognition and global function [ Time Frame: 9 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00818662 on ClinicalTrials.gov Archive Site
  • Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) [ Time Frame: Baseline & 9 months ] [ Designated as safety issue: No ]

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.

    Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

  • Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) [ Time Frame: Baseline & 9 Months ] [ Designated as safety issue: No ]

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.

    Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

  • Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment [ Time Frame: Baseline & 9 Months ] [ Designated as safety issue: No ]

    The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.

    A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).

    1. Very much better
    2. Much better
    3. A little better
    4. Same
    5. A little worse
    6. Much worse
    7. Very much worse
  • Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment [ Time Frame: Baseline & 18 Months ] [ Designated as safety issue: No ]

    The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.

    A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).

    1. Very much better
    2. Much better
    3. A little better
    4. Same
    5. A little worse
    6. Much worse
    7. Very much worse
  • Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.
  • Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
  • Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
  • Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category "animals" as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
  • Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test [ Time Frame: Baseline & 18 months ] [ Designated as safety issue: No ]
    In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).
  • Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
  • Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
  • Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
    Related and unrelated non-SAEs
  • Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
    Related and unrelated SAEs
  • Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs) [ Time Frame: During or within 72 hours of completion of an infusion ] [ Designated as safety issue: Yes ]
    Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)
  • Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs) [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
    Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered
  • Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE) [ Time Frame: Throughout each infusion period ] [ Designated as safety issue: Yes ]
  • Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
  • Number of Participants Experiencing a Clinically Significant Rash [ Time Frame: Throughout the study period, approximately 4 years ] [ Designated as safety issue: Yes ]
    Participants requiring systemic therapy or discontinuation from further treatment
  • Cognition and global function [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Activities of daily living, behavior, and quality of life [ Time Frame: 9 and 18 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).

Study visits: Each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Alzheimer´s Disease
  • Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
    400 mg/kg bodyweight every 2 weeks for 70 weeks
    Other Names:
    • Gammagard Liquid
    • KIOVIG
  • Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
    200 mg/kg bodyweight every 2 weeks for 70 weeks
    Other Name: Gammagard Liquid
  • Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
    Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
  • Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
    Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
  • Experimental: IGIV, 10% 400mg/kg
    Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
    Intervention: Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
  • Experimental: IGIV, 10% 200mg/kg
    Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
    Intervention: Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
  • Placebo Comparator: Human Albumin 0.25% Solution - 4 mL/kg
    0.25% human albumin solution infused at 4 mL/kg/2weeks
    Intervention: Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
  • Placebo Comparator: Human Albumin 0.25% Solution - 2 mL/kg
    0.25% human albumin solution infused at 2 mL/kg/2weeks
    Intervention: Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
390
December 2012
December 2012   (final data collection date for primary outcome measure)

Main Inclusion Criteria:

  • Written informed consent - participant (or participant´s legally acceptable representative) and caregiver who are willing and able to participate for the duration of the study
  • Diagnosis of probable Alzheimer´s Disease (AD)
  • Dementia of mild to moderate severity defined as mini-mental state examination (MMSE) 16-26 inclusive at the time of screening
  • Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset consistent with AD diagnosis
  • Ability to comply with testing and infusion regimen, including fluency in English or Spanish, adequate corrected visual acuity and hearing ability
  • On stable doses of regulatory authority approved AD medication(s) for at least 3 months prior to screening. These medications must be continued throughout this study.
  • If receiving psychoactive medications (e.g. antidepressants other than monoamine oxidase inhibitors (MAOIs) and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc), must be on stable doses for at least 6 weeks prior to screening

Main Exclusion Criteria (Reasons why it might not be appropriate to participate):

  • Any other forms of dementia
  • Medical issues that might increase the risk of treatment with IGIV, 10%, such as:

    1. Significant problems with blood pressure, heart disease, clotting disorders, strokes or recent heart attacks
    2. Evidence of current bleeding in the brain by MRI
    3. Serious problems with the liver or kidneys
    4. Allergies to blood products
  • Medical issues that might interfere with the evaluation of the treatment of dementia or might make dementia worse, such as:

    1. Diabetes
    2. Recent treatment with chemotherapy or immune suppression
    3. The recent use of other investigational drugs, especially antibody therapy for AD
    4. Severe headaches or psychiatric problems
Both
50 Years to 89 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00818662
160701
Yes
Baxter Healthcare Corporation
Baxter Healthcare Corporation
Alzheimer's Disease Cooperative Study (ADCS)
Study Director: Norman Relkin, MD, PhD Alzheimer's Disease Cooperative Study (ADCS)
Study Director: David Gelmont, MD Baxter Healthcare Corporation
Baxter Healthcare Corporation
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP